Rankings
▼
Calendar
CTMX Q2 2016 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
CTMX
CytomX Therapeutics, Inc.
$827M
Q2 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$3M
Gross Profit
$3M
100.0% margin
Operating Income
-$14M
-460.8% margin
Net Income
-$14M
-458.2% margin
EPS (Diluted)
$-0.39
QoQ Revenue Growth
+39.2%
Cash Flow
Operating Cash Flow
$16M
Free Cash Flow
$15M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$207M
Total Liabilities
$106M
Stockholders' Equity
$101M
Cash & Equivalents
$62M
← FY 2016
All Quarters
Q3 2016 →